Photo of Arnold S. Freedman,  MD

Arnold S. Freedman, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-3441
Fax: (617) 632-5235


arnold_freedman@dfci.harvard.edu

Arnold S. Freedman, MD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Professor, Medicine, Harvard Medical School

DF/HCC PROGRAM AFFILIATION

Research Abstract

My laboratory focus is on how the malignant microenvironment affects the growth and survival of B cell leukemias and lymphomas. This involves studies of supportive cells and the cell-cell contact and soluble factors which they provide for malignant B cells. In the area of clinical research, I have focused on the role of high dose therapy in indolent lymphomas and strategies to improve this treatment. This includes improvements in purging tumor cells from the normal hematopoietic stem cells and post-transplant therapies using immunotherapeutic approaches with cytokines and monoclonal antibodies.

Publications

Powered by Harvard Catalyst
  • Jacobson CA, Freedman AS. Rethinking Prognosis and Therapy for Follicular Lymphoma. J Clin Oncol 2015. PubMed
  • Jacobsen E, Pozdnyakova O, Redd R, Fisher DC, Dorfman DM, Dal Cin P, LaCasce A, Armand P, Hochberg E, Cote G, Shahsafaei A, Neuberg D, Brown JR, Freedman AS. Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma. Leuk Lymphoma 2015. PubMed
  • Jacobson CA, Freedman AS. Is observation dead in follicular lymphoma? Still appropriate. J Natl Compr Canc Netw 2015; 13:367-70. PubMed
  • Ganapathi KA, Pittaluga S, Odejide OO, Freedman AS, Jaffe ES. Early lymphoid lesions: conceptual, diagnostic and clinical challenges. Haematologica 2014; 99:1421-32. PubMed
  • Levy R, Ganjoo KN, Leonard JP, Vose JM, Flinn IW, Ambinder RF, Connors JM, Berinstein NL, Belch AR, Bartlett NL, Nichols C, Emmanouilides CE, Timmerman JM, Gregory SA, Link BK, Inwards DJ, Freedman AS, Matous JV, Robertson MJ, Kunkel LA, Ingolia DE, Gentles AJ, Liu CL, Tibshirani R, Alizadeh AA, Denney DW. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. J Clin Oncol 2014; 32:1797-803. PubMed
  • Rendleman J, Antipin Y, Reva B, Adaniel C, Przybylo JA, Dutra-Clarke A, Hansen N, Heguy A, Huberman K, Borsu L, Paltiel O, Ben-Yehuda D, Brown JR, Freedman AS, Sander C, Zelenetz A, Klein RJ, Shao Y, Lacher M, Vijai J, Offit K, Kirchhoff T. Genetic variation in DNA repair pathways and risk of non-Hodgkin's lymphoma. PLoS ONE 2014; 9:e101685. PubMed
  • Fanale M, Assouline S, Kuruvilla J, Solal-CĂ©ligny P, Heo DS, Verhoef G, Corradini P, Abramson JS, Offner F, Engert A, Dyer MJ, Carreon D, Ewald B, Baeck J, Younes A, Freedman AS. Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. British Journal of Haematology 2014; 164:258-65. PubMed
  • Armand P, Oki Y, Neuberg DS, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, Lacasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Fowler NH, Alma Rodriguez M, Wallace MJ, Neelapu SS, Rodig S, Younes A, Freedman AS. Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. British Journal of Haematology 2013; 163:123-6. PubMed
  • Jacobson CA, Freedman AS. One size does not fit all in follicular lymphoma. J Clin Oncol 2013; 31:3307-8. PubMed
  • Brown JR, Messmer B, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, LaCasce AS, Armand P, Jacobsen E, Dalton V, Tesar B, Fernandes SM, McDonough S, Ritz J, Rassenti L, Kipps TJ, Neuberg D, Freedman AS. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica 2013. PubMed
  • Jacobson CA, Freedman AS. First-line treatment of indolent lymphoma: axing CHOP? Lancet 2013; 381:1163-5. PubMed
  • Barnes JA, Jacobsen E, Feng Y, Freedman A, Hochberg EP, LaCasce AS, Armand P, Joyce R, Sohani AR, Rodig SJ, Neuberg D, Fisher DC, Abramson JS. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica 2013. PubMed
  • Armand P, Welch S, Kim HT, LaCasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Coughlin E, Freedman AS, Chen YB. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. British Journal of Haematology 2013; 160:608-17. PubMed
  • Giardino AA, Shinagare AB, Shinagare SA, Dewar R, Weckstein D, Mauch P, Ramaiya NH, Freedman AS. Primary bone lymphoma involving bilateral tibia. Am J Hematol 2012; 87:924-5. PubMed
  • Brown JR, Hanna M, Tesar B, Werner L, Pochet N, Asara JM, Wang YE, Dal Cin P, Fernandes SM, Thompson C, Macconaill L, Wu CJ, Van de Peer Y, Correll M, Regev A, Neuberg D, Freedman AS. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res 2012; 18:3791-802. PubMed
  • Furman RR, Grossbard ML, Johnson JL, Pecora AL, Cassileth PA, Jung SH, Peterson BA, Nadler LM, Freedman A, Bayer RL, Bartlett NL, Hurd DD, Cheson BD, , . A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leuk Lymphoma 2011; 52:587-96. PubMed
  • Sweetenham JW, Freedman AS. Early initial therapy of advanced follicular lymphoma: the need for vigilance. Leuk Lymphoma 2011; 52:355-7. PubMed
  • Setlur SR, Ihm C, Tchinda J, Shams S, Werner L, Cho EK, Thompson C, Phillips K, Rassenti LZ, Kipps TJ, Neuberg D, Freedman AS, Lee C, Brown JR. Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization. British Journal of Haematology 2010; 151:336-45. PubMed
  • Yoon SO, Zhang X, Freedman AS, Zahrieh D, Lossos IS, Li L, Choi YS. Down-regulation of CD9 expression and its correlation to tumor progression in B lymphomas. Am J Pathol 2010; 177:377-86. PubMed
  • Pozdnyakova O, Spieler PJ, Abraham J, Freedman AS, Kutok JL. Epstein-barr virus-associated diffuse large B-cell lymphoma in an immunocompetent woman. J Clin Oncol 2010; 28:e75-8. PubMed
  • Friedberg JW, Kelly JL, Neuberg D, Peterson DR, Kutok JL, Salloum R, Brenn T, Fisher DC, Ronan E, Dalton V, Rich L, Marquis D, Sims P, Rothberg PG, Liesveld J, Fisher RI, Coffman R, Mosmann T, Freedman AS. Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. British Journal of Haematology 2009; 146:282-91. PubMed
  • Brown JR, Freedman AS. ASCT in follicular lymphoma. Nat Rev Clin Oncol 2009; 6:380-2. PubMed
  • Brown JR,Friedberg JW,Feng Y,Scofield S,Phillips K,Dal Cin P,Joyce R,Takvorian RW,Fisher DC,Fisher RI,Liesveld J,Marquis D,Neuberg D,Freedman AS. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. British Journal of Haematology 2009; 145:741-8. PubMed
  • Armand P,Gannamaneni S,Kim HT,Cutler CS,Ho VT,Koreth J,Alyea EP,LaCasce AS,Jacobsen ED,Fisher DC,Brown JR,Canellos GP,Freedman AS,Soiffer RJ,Antin JH. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 2008; 26:5767-74. PubMed
  • Luthy SK,Ng AK,Silver B,Degnan KO,Fisher DC,Freedman AS,Mauch PM. Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma. Ann Oncol 2008; 19:2043-7. PubMed
  • Brown JR,Neuberg D,Phillips K,Reynolds H,Silverstein J,Clark JC,Ash M,Thompson C,Fisher DC,Jacobsen E,LaCasce AS,Freedman AS. Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders. British Journal of Haematology 2008; 143:361-8. PubMed
  • Brown JR, Levine RL, Thompson C, Basile G, Gilliland DG, Freedman AS. Systematic genomic screen for tyrosine kinase mutations in CLL. Leukemia 2008; 22:1966-9. PubMed
  • Friedberg J, Jacobsen E, Neuberg D, Kutok J, Munoz O, Boussiotis V, Reynolds H, Fisher D, Szot A, Van Den Abbeele A, Freedman A. Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept. Leuk Lymphoma 2008; 49:902-9. PubMed
  • Lacasce AS, Freedman AS. Antibody and Immunomodulatory Agents in the Treatment of Indolent Non-Hodgkin's Lymphoma. Semin Hematol 2008; 45:85-9. PubMed
  • Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008; 14:418-25. PubMed
  • Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P, Nadler LM, Freedman AS. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant 2007; 13:1057-65. PubMed
  • Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J, Gribben JG, Mauch PM, Lister TA, Freedman AS. Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma at the Time of Second or Subsequent Remission: Long-Term Follow-Up. J Clin Oncol 2007; 25:2554-9. PubMed
  • Friedberg JW, Freedman AS. Antibody and immunomodulatory agents in treatment of indolent non-Hodgkin's lymphoma. Curr Treat Options Oncol 2006; 7:276-84. PubMed
  • Zubair AC, Kao G, Daley H, Schott D, Freedman A, Ritz J. CD34(+) CD38(-) and CD34(+) HLA-DR(-) cells in BM stem cell grafts correlate with short-term engraftment but have no influence on long-term hematopoietic reconstitution after autologous transplantation. Cytotherapy 2006; 8:399-407. PubMed
  • Freedman AS. Non-transplant-related treatment options in follicular lymphoma. Biol Blood Marrow Transplant 2006; 12:53-8. PubMed
  • Brown JR, Yeckes H, Friedberg JW, Neuberg D, Kim H, Nadler LM, Freedman AS. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:2208-14. PubMed
Hide